<DOC>
	<DOCNO>NCT01242215</DOCNO>
	<brief_summary>This study evaluate efficacy safety concomitant administration ASP1941 sulfonylurea patient diabetes mellitus .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety ASP1941 Combination With Sulfonylurea Type 2 Diabetic Patients</brief_title>
	<detailed_description>This study evaluate efficacy safety ASP1941 combination sulfonylurea subject type 2 diabetes mellitus ( T2DM ) inadequate glycemic control sulfonylurea alone . The effect ASP1941 compare placebo . Double blind period continue 24 week follow open period patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 diabetic patient receive sulfonylurea monotherapy least 4 week HbA1c value 7.0 9.5 % Body Mass Index ( BMI ) 20.0 45.0 kg/m2 Type 1 diabetes mellitus patient Serum creatinine &gt; upper limit normal Proteinuria ( albumin/creatinine ratio &gt; 300mg/g ) Dysuria and/or urinary tract infection , genital infection Significant renal , hepatic cardiovascular disease Severe gastrointestinal disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>ASP1941</keyword>
	<keyword>Diabetes mellitus</keyword>
	<keyword>sulfonylurea</keyword>
</DOC>